View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 03, 2017
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	AQB
Entity Registrant Name	Aquabounty Technologies, Inc.
Entity Central Index Key	0001603978
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		8,895,094

Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 7,991,382	$ 3,324,609
Certificate of deposit	12,972	10,666
Other receivables	161,039	164,743
Inventory	78,275	0
Prepaid expenses and other current assets	352,772	72,983
Total current assets	8,596,440	3,573,001
Property, plant and equipment, net	17,906,075	1,723,707
Definite-lived intangible assets, net	191,847	198,698
Indefinite-lived intangible assets	191,800	191,800
Other assets	21,628	21,628
Total assets	26,907,790	5,708,834
Current liabilities:
Accounts payable and accrued liabilities	949,495	1,017,851
Current debt	53,089	17,913
Total current liabilities	1,002,584	1,035,764
Long-term debt	2,952,668	2,645,015
Total liabilities	3,955,252	3,680,779
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized; 8,895,094 (2016: 6,463,936) shares outstanding	8,895	6,464
Additional paid-in capital	126,644,804	101,581,724
Accumulated other comprehensive loss	(278,121)	(286,272)
Accumulated deficit	(103,423,040)	(99,273,861)
Total stockholders’ equity	22,952,538	2,028,055
Total liabilities and stockholders’ equity	$ 26,907,790	$ 5,708,834

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares outstanding	8,895,094	6,463,936

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues
Product revenues	$ 53,278	$ 0	$ 53,278	$ 0
Costs and expenses
Product costs	50,777	0	50,777	0
Sales and marketing	202,910	239,142	411,198	440,519
Research and development	936,317	915,741	1,656,339	1,730,998
General and administrative	950,348	824,138	2,071,136	1,603,663
Total costs and expenses	2,140,352	1,979,021	4,189,450	3,775,180
Operating loss	(2,087,074)	(1,979,021)	(4,136,172)	(3,775,180)
Other income (expense)
Gain on disposal of equipment	0	0	0	2,861
Interest expense	(5,253)	(83,333)	(10,533)	(107,639)
Other income (expense), net	(1,109)	(1,482)	(2,474)	(2,855)
Total other income (expense)	(6,362)	(84,815)	(13,007)	(107,633)
Net loss	(2,093,436)	(2,063,836)	(4,149,179)	(3,882,813)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	22,437	(3,182)	8,151	(100,175)
Total other comprehensive income (loss)	22,437	(3,182)	8,151	(100,175)
Comprehensive loss	$ (2,070,999)	$ (2,067,018)	$ (4,141,028)	$ (3,982,988)
Basic and diluted net loss per share (in dollars per share)	$ (0.24)	$ (0.39)	$ (0.48)	$ (0.74)
Weighted average number of common shares -
basic and diluted (in shares)	8,892,213	5,250,504	8,647,861	5,249,405

Consolidated Statements of Changes in Stockholders' Equity - 6 months ended Jun. 30, 2017 - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning Balance at Dec. 31, 2016	$ 2,028,055	$ 6,464	$ 101,581,724	$ (286,272)	$ (99,273,861)
Beginning Balance, outstanding (in shares) at Dec. 31, 2016		6,463,936
Beginning Balance, issued (in shares) at Dec. 31, 2016		6,463,936
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,149,179)				(4,149,179)
Other comprehensive loss	8,151			8,151
Issuance of common stock, net of expenses	24,989,257	$ 2,421	24,986,836
Issuance of common stock, net of expenses (in shares)		2,421,073
Exercise of options for common stock	$ 27,502	$ 8	27,494
Exercise of options for common stock (in shares)	8,334	8,334
Share based compensation	$ 48,752	$ 2	48,750
Share based compensation (in shares)		1,751
Ending Balance at Jun. 30, 2017	$ 22,952,538	$ 8,895	$ 126,644,804	$ (278,121)	$ (103,423,040)
Ending Balance, outstanding (in shares) at Jun. 30, 2017		8,895,094
Ending Balance, issued (in shares) at Jun. 30, 2017		8,895,094

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net loss	$ (4,149,179)	$ (3,882,813)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	91,569	64,728
Share-based compensation	48,752	114,662
Gain on disposal of equipment	0	(2,861)
Changes in operating assets and liabilities:
Other receivables	7,853	20,640
Inventory	(78,275)	0
Prepaid expenses and other assets	(279,058)	(129,771)
Accounts payable and accrued liabilities	(38,702)	178,434
Net cash used in operating activities	(4,397,040)	(3,636,981)
Investing activities
Purchase of property, plant and equipment	(16,193,926)	(728,748)
Proceeds from sale of equipment	0	2,861
Payment of patent costs	0	(5,665)
Net cash used in investing activities	(16,193,926)	(731,552)
Financing activities
Proceeds from issuance of debt	256,807	0
Repayment of term debt	(11,405)	0
Proceeds from the issuance of convertible debt	0	5,000,000
Proceeds from the issuance of common stock, net	24,989,257	0
Proceeds from the exercise of stock options	27,502	0
Net cash provided by financing activities	25,262,161	5,000,000
Effect of exchange rate changes on cash and cash equivalents	(4,422)	(15,229)
Net change in cash and cash equivalents	4,666,773	616,238
Cash and cash equivalents at beginning of period	3,324,609	1,313,421
Cash and cash equivalents at the end of period	7,991,382	1,929,659
Supplemental disclosure of cash flow information and non-cash transactions:
Interest paid in cash	10,533	0
Property and equipment included in accounts payable	$ 16,218	$ 0

Nature of business and organization	6 Months Ended
Nature of business and organization	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and organization	Nature of business and organization AquaBounty Technologies, Inc. (the “Parent” and, together with its subsidiaries, the “Company”) was incorporated in December 1991 in the State of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm‑raised Atlantic salmon that exhibit growth rates that are substantially faster than traditional salmon. In 2015, the Parent obtained approval from the US Food and Drug Administration (the “FDA”) for the production, sale, and consumption of its AquAdvantage® Salmon product in the United States. In 2016, the Parent obtained approval from Health Canada, the department of the government of Canada responsible for national public health, for the sale and consumption of its AquAdvantage Salmon product in Canada. Previously, in 2013, the Parent obtained approval from Environment Canada, the agency of the government of Canada responsible for regulating environmental policies and issues, for the production of the product. AQUA Bounty Canada Inc. (the “Canadian Subsidiary”) was incorporated in January 1994 in Canada for the purpose of establishing a commercial biotechnology laboratory to conduct research and development programs related to the Parent’s technologies. AquaBounty Panama, S. de R.L. (the “Panama Subsidiary”) was incorporated in May 2008 in Panama for the purpose of conducting commercial trials of the Company’s AquAdvantage Salmon. AquaBounty Farms, Inc. (“AquaBounty Farms”) was incorporated in December 2014 in the State of Delaware for the purpose of conducting field trials and commercializing the Company’s AquAdvantage Salmon in the United States. AquaBounty Farms Indiana LLC (the “Indiana Subsidiary”) was formed in June 2017 in the State of Delaware for the purpose of operating the Company’s aquaculture facility in Albany, Indiana, and is wholly owned by AquaBounty Farms. AquaBounty Brasil Participações Ltda. (the “Brazil Subsidiary”) was incorporated in May 2015 in Brazil for the purpose of conducting commercial trials of the Company’s AquAdvantage Salmon.

Basis of presentation	6 Months Ended
Basis of presentation	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The unaudited interim consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct and indirect subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC; and AquaBounty Brasil Participações Ltda. All inter-company transactions and balances have been eliminated upon consolidation. The unaudited interim consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2016. The unaudited interim consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of June 30, 2017, and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. On January 5, 2017, the Company implemented a 1-for-30 reverse share split of its outstanding common shares. All share balances in the unaudited interim consolidated financial statements and accompanying notes have been restated to reflect this change. Net loss per share Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Basic net loss is based solely on the number of common shares outstanding during the year. Fully diluted net loss per share includes the number of shares of common stock issuable upon the exercise of warrants and options with an exercise price less than the fair value of the common stock. Since the Company is reporting a net loss for all periods presented, all potential common shares are considered anti‑dilutive and are excluded from the calculation of diluted net loss per share. Accounting Pronouncements The Company has adopted Accounting Standards Update (“ASU”) 2017-01, “Business Combinations: Clarifying the Definition of a Business.” The revised guidance changes the definition of a business to assist entities with evaluating whether a set of transferred assets and activities is a business. During the quarter ended June 30, 2017, the Company acquired certain assets of Bell Fish Company LLC in Albany, Indiana, for $14.2 million, including legal and other expenses incurred (see Note 5). The facility and related assets acquired will be renovated and used to grow and harvest the Company's AquAdvantage Salmon. After upgrading the facility to comply with regulatory requirements, the Company will utilize its grow-out process, personnel, and AquAdvantage Salmon eggs to produce harvest-sized Atlantic salmon for sale in the United States. The facility and related assets acquired provide one input into the Company's process for growing its product, and, accordingly, the purchase of the facility was accounted for as an asset purchase. The Company has adopted ASU 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements in Accounting Standard Codification (“ASC”) 605, “Revenue Recognition,” and most industry-specific guidance throughout the ASC. ASU 2014-09 established principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In applying ASU 2014-09, the Company identifies the performance obligation in the contract, determines the transaction price, allocates the transaction price to the performance obligations, and recognizes revenue upon completion of the performance obligation. During the quarter ended June 30, 2017, the Company completed its first sales of AquAdvantage Salmon. Sales orders contain a single deliverable, AquAdvantage Salmon, and revenue is recognized upon delivery. The Company has adopted ASU 2015-11, “Inventory: Simplifying the Measurement of Inventory.” The main provision of the guidance is that an entity should measure inventory at the lower of cost or net realizable value (“NRV”), where NRV is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company has adopted ASU 2016-09, “Compensation – Stock Compensation.” The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Adoption of this ASU did not have a material impact on the financial statements. Liquidity and Management’s Plan At June 30, 2017, the Company’s cash balance totaled $8.0 million. Management has evaluated the Company’s cash resources in view of its planned spending for ongoing operations, capital expenditures, and working capital for the next twelve months and has determined that its current funds are insufficient for these needs. However, management does not believe that there is substantial doubt that the Company can continue as a going concern. Management’s assessment is based on its belief that the Company will be able to raise additional equity or debt to fund its requirements. Additionally, management could slow down spending to conserve the Company’s cash if there is a delay in obtaining new funding. Therefore, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Risks and uncertainties	6 Months Ended
Risks and uncertainties	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Risks and uncertainties	Risks and uncertainties The Company is subject to risks and uncertainties common in the biotechnology and aquaculture industries. Such risks and uncertainties include, but are not limited to: (i) results from current and planned product development studies and trials; (ii) decisions made by the FDA or similar regulatory bodies in other countries with respect to approval and commercial sale of any of the Company’s proposed products; (iii) the commercial acceptance of any products approved for sale and the Company’s ability to manufacture, distribute, and sell for a profit any products approved for sale; (iv) the Company’s ability to obtain the necessary patents and proprietary rights to effectively protect its technologies; and (v) the outcome of any collaborations or alliances entered into by the Company. Concentration of credit risk Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and certificates of deposit. This risk is minimized by the Company’s policy of investing in financial instruments with short-term maturities issued by highly rated financial institutions. The Company’s cash balances may at times exceed insurance limitations. The Company holds cash balances in bank accounts located in Canada to fund its local operations. These amounts are subject to foreign currency exchange risk, which is mitigated by the Company’s policy to limit the balances held in these accounts. Balances in Canadian bank accounts totaled $90,926 at June 30, 2017. Financial instruments The carrying amounts reported in the consolidated balance sheets for other receivables and accounts payable approximate fair value based on the short-term maturity of these instruments. The carrying value of term debt approximates its fair value since it provides for market terms and interest rates. Included in other assets is a long-term investment that consists of 216,281 shares of common stock of A/F Protein, Inc. (“AFP”), equating to less than 1% ownership, with a cost basis of $21,628, which the Company believes to be the best estimate of market value.

Inventory

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventory

Major classifications of inventory are summarized as follows:



	June 30,		December 31,
	2017		2016
Feed	$	53,693	$	—
Fish in process	24,582		—
Total inventory	$	78,275	$	—

Property, plant and equipment

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property, plant and equipment

Major classifications of property, plant and equipment are summarized as follows:



	June 30,			December 31,
	2017			2016
Land	$	611,960		$	157,107
Building and improvements	8,558,012			1,436,814
Construction in process	2,235,659			277,352
Equipment	7,814,922			1,037,549
Office furniture and equipment	80,039			78,780
Vehicles	28,170			27,201
Total property and equipment	$	19,328,762		$	3,014,803
Less accumulated depreciation and amortization	(1,422,687		)	(1,291,096		)
Property, plant and equipment, net	$	17,906,075		$	1,723,707

Depreciation and amortization expense was $84,717 and $58,054 for the six months ended June 30, 2017 and 2016, respectively.

Included as construction in process is $2.2 million for renovation and new construction costs incurred at our Rollo Bay farm site. The Company currently has an additional $2.4 million committed to these renovations.

On June 22, 2017, the Company purchased the aquaculture facility of Bell Fish Company LLC in Albany, Indiana, for $14.2 million, including legal and other expenses incurred. There are no future obligations related to the asset purchase for the Company, no liabilities were assumed, and no workforce was acquired. The Company allocated the purchase price to land, buildings, and equipment based on external valuations and management’s estimates. The Company intends to invest approximately $1.5 million to upgrade the facility for use to grow out its AquAdvantage Salmon for harvest and sale in the United States.

Accounts payable and accrued liabilities

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities include the following:



	June 30,		December 31,
	2017		2016
Accounts payable	$	366,927	$	161,768
Accrued payroll including vacation	244,077		242,436
Accrued professional fees	143,487		500,430
Accrued research and development costs	100,650		87,751
Accrued taxes	94,354		22,994
Accrued other	—		2,472
Accounts payable and accrued liabilities	$	949,495	$	1,017,851

Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Debt

The current material terms and conditions of debt outstanding are as follows:



	Interest rate	Monthly repayment	Maturity date	June 30, 2017			December 31, 2016
ACOA AIF grant (C$2,871,919)	0%	Royalties	-	$	2,211,952		$	2,135,846
ACOA term loan (C$337,000)	0%	C$3,120	June 2026	257,154			—
Finance PEI term loan (C$717,093)	4%	C$4,333	July 2021	536,651			527,082
Total debt				$	3,005,757		$	2,662,928
less: current portion				(53,089		)	(17,913		)
Long-term debt				$	2,952,668		$	2,645,015

Estimated principal payments due on loan debt are as follows (1):



Year	Total
2017	$	23,757
2018	58,144
2019	100,630
2020	262,247
2021	1,994,536
Thereafter	566,443
Total	$	3,005,757

(1) Repayments of the AIF grants are based on revenue projections for AquAdvantage Salmon.

Atlantic Canada Opportunities Agency (“ACOA”)

ACOA is a Canadian government agency that provides funding to support the development of businesses and to promote employment in the Atlantic region of Canada.

In January 2009, the Canadian Subsidiary was awarded a grant from ACOA to provide a contribution towards the funding of a research and development project. The total amount claimed under the award over the five-year claim period was $2,211,952. No further funds are available under this grant. Amounts claimed by the Canadian Subsidiary must be repaid in the form of a 10% royalty on any products that are commercialized out of this research project until the loan is fully repaid. The first scheduled repayment was June 30, 2015, and subsequent repayments are due annually until the full balance of the contributed funds is paid. The Company expects to make its first repayment in 2018.

In February 2016, the Canadian Subsidiary executed an agreement with ACOA to partially finance the renovations to the Rollo Bay site. The terms of the agreement include funding up to $259,557 with repayment commencing after the final draw-down of the funds. The loan term is nine years with a zero percent interest rate. As of June 30, 2017, the Canadian Subsidiary has drawn down the full amount of available funds and commenced repayment.

Finance PEI (“FPEI”)

FPEI is a corporation of the Ministry of Economic Development and Tourism for Prince Edward Island, Canada, and administers business financing programs for the provincial government. In August 2016, the Canadian Subsidiary obtained a loan from FPEI in the amount of $552,305 to partially finance the purchase of the assets of the former Atlantic Sea Smolt plant in Rollo Bay West on Prince Edward Island. The loan is being repaid through monthly payments of principal and interest with a balloon payment for the balance due in July 2021. The loan is collateralized by a mortgage executed by the Canadian Subsidiary, which conveys a first security interest in all of its current and acquired assets. The loan is guaranteed by the Parent.

The Company recognized interest expense of $10,523 and $107,639 for the six months ended June 30, 2017 and 2016, respectively, on its interest-bearing debt.

Stockholders' equity

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' equity

Stockholders’ equity

The Company is presently authorized to issue up to 240 million shares of stock, of which 40 million are authorized as preferred stock and 200 million as common stock.

Common stock

The holders of the common stock are entitled to one vote for each share held at all meetings of stockholders. Dividends and distribution of assets of the Company in the event of liquidation are subject to the preferential rights of any outstanding preferred shares. At June 30, 2017, the Company had reserved 227,203 shares of common stock for the exercise of options.

Restricted stock

The Company grants restricted common stock to the Chairman of the Board of Directors as part of his compensation package. Generally, the shares are fully vested upon the third anniversary of the grant date. Unvested shares can be canceled upon termination of the Chairman’s services.

A summary of the Company’s unvested shares of restricted stock as of June 30, 2017, is as follows:



	Shares		Weighted average grant date fair value
Unvested at December 31, 2016	4,169		$	7.72
Granted	1,751		14.20
Vested	(1,532	)	7.88
Unvested at June 30, 2017	4,388		$	10.25

During the six months ended June 30, 2017 and 2016, the Company expensed $12,070 and $8,260, respectively, related to the Chairman’s restricted stock awards. At June 30, 2017, the balance of unearned share-based compensation to be expensed in future periods related to the restricted stock awards is $44,982. The period over which the unearned share-based compensation is expected to be earned is approximately three years.

Stock options

In 2006, the Company established its 2006 Equity Incentive Plan (the “2006 Plan”). The 2006 Plan provided for the issuance of incentive stock options to employees of the Company and non‑qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of the Company. In accordance with its original terms, no further shares may be granted under the 2006 Plan subsequent to March 18, 2016. All outstanding awards under the 2006 Plan will continue until their individual termination dates.

In March 2016, the Company’s Board of Directors adopted the AquaBounty Technologies, Inc. 2016 Equity Incentive Plan (the “2016 Plan”) to replace the 2006 Plan. The 2016 Plan provides for the issuance of incentive stock options, non‑qualified stock options, and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of the Company. The aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2016 Plan cannot exceed 450,000. The 2016 Plan was approved by the Company’s shareholders at its Annual Meeting on April 26, 2016.

The Company’s option activity under the 2006 Plan and the 2016 Plan is summarized as follows:



	Number of options		Weighted average exercise price
Outstanding at December 31, 2016	185,591		$	7.89
Issued	52,500		14.20
Exercised	(8,334	)	3.30
Expired	(2,554	)	19.50
Outstanding at June 30, 2017	227,203		$	9.39
Exercisable at June 30, 2017	179,500		$	8.17

Unless otherwise indicated, options issued to employees, members of the Board of Directors, and non-employees are vested over one to three years and are exercisable for a term of ten years from the date of issuance.

The weighted average fair value of stock options granted during the six months ended June 30, 2017, was $4.55. The intrinsic value of options exercised during the six months ended June 30, 2017, was $43,420. The total intrinsic value of all options outstanding was $441,390 and $602,773 at June 30, 2017, and December 31, 2016, respectively. The total intrinsic value of exercisable options was $439,494 and $597,872 at June 30, 2017, and December 31, 2016, respectively.

The following table summarizes information about options outstanding and exercisable at June 30, 2017:



Weighted average exercise price of outstanding options	Number of options outstanding	Weighted average remaining estimated life (in years)	Number of options exercisable	Weighted average exercise price of outstanding and exercisable options
$3.30	79,337	2.0	79,337
$3.60	800	5.0	800
$5.70	10,336	7.7	10,006
$6.90	29,038	3.9	28,016
$7.50	15,837	5.8	15,837
$9.60	8,300	8.2	8,300
$9.90	800	1.0	800
$10.50	1,600	6.0	1,600
$10.80	2,400	7.0	2,400
$14.20	52,500	9.8	6,149
$23.40	26,255	6.6	26,255
	227,203		179,500	$8.17

Total share-based compensation on stock-option grants amounted to $36,682 and $106,402 for the six months ended June 30, 2017 and 2016, respectively. At June 30, 2017, the balance of unearned share-based compensation to be expensed in future periods related to unvested share-based awards was $216,447. The period over which the unearned share-based compensation is expected to be earned is approximately three years.

Commitments and contingencies	6 Months Ended
Commitments and contingencies	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies The Company recognizes and discloses commitments when it enters into executed contractual obligations with other parties. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than the extension of the Maynard office lease (see Note 11), there have been no material changes to the commitments and contingencies disclosed in our annual report on Form 10-K as of and for the year ended December 31, 2016.

Related Party Collaboration Agreement	6 Months Ended
Related Party Collaboration Agreement	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Collaboration Agreement	Related Party Collaboration Agreement In February 2013, the Company entered into an Exclusive Channel Collaboration agreement (“ECC”) with Intrexon Corporation, its majority shareholder (“Intrexon”), pursuant to which the Company will use Intrexon’s UltraVector and other technology platforms to develop and commercialize additional genetically modified traits in finfish for human consumption. Total Intrexon service costs incurred under the terms of this agreement for the six months ended June 30, 2017 and 2016, amounted to $315,116 and $489,083, respectively, and are included as a component of research and development expense in Consolidated Statements of Operations and Comprehensive Loss. Included in accounts payable and accrued liabilities at June 30, 2017, and December 31, 2016, are amounts due to Intrexon under the ECC totaling $49,119 and $73,780, respectively.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In July 2017, the Company extended the lease for its office space in Maynard, Massachusetts. The new lease has a term of five years and seven months, ending March 2023, with total annual rent payments of approximately $60 thousand increasing to $68 thousand during the term of the lease.

Basis of presentation (Policies)	6 Months Ended
Basis of presentation (Policies)	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation	The unaudited interim consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct and indirect subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC; and AquaBounty Brasil Participações Ltda. All inter-company transactions and balances have been eliminated upon consolidation.
Basis of presentation	The unaudited interim consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2016. The unaudited interim consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of June 30, 2017, and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.
Net loss per share	Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Basic net loss is based solely on the number of common shares outstanding during the year. Fully diluted net loss per share includes the number of shares of common stock issuable upon the exercise of warrants and options with an exercise price less than the fair value of the common stock. Since the Company is reporting a net loss for all periods presented, all potential common shares are considered anti‑dilutive and are excluded from the calculation of diluted net loss per share.
Accounting Pronouncements	The Company has adopted Accounting Standards Update (“ASU”) 2017-01, “Business Combinations: Clarifying the Definition of a Business.” The revised guidance changes the definition of a business to assist entities with evaluating whether a set of transferred assets and activities is a business. During the quarter ended June 30, 2017, the Company acquired certain assets of Bell Fish Company LLC in Albany, Indiana, for $14.2 million, including legal and other expenses incurred (see Note 5). The facility and related assets acquired will be renovated and used to grow and harvest the Company's AquAdvantage Salmon. After upgrading the facility to comply with regulatory requirements, the Company will utilize its grow-out process, personnel, and AquAdvantage Salmon eggs to produce harvest-sized Atlantic salmon for sale in the United States. The facility and related assets acquired provide one input into the Company's process for growing its product, and, accordingly, the purchase of the facility was accounted for as an asset purchase. The Company has adopted ASU 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements in Accounting Standard Codification (“ASC”) 605, “Revenue Recognition,” and most industry-specific guidance throughout the ASC. ASU 2014-09 established principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In applying ASU 2014-09, the Company identifies the performance obligation in the contract, determines the transaction price, allocates the transaction price to the performance obligations, and recognizes revenue upon completion of the performance obligation. During the quarter ended June 30, 2017, the Company completed its first sales of AquAdvantage Salmon. Sales orders contain a single deliverable, AquAdvantage Salmon, and revenue is recognized upon delivery. The Company has adopted ASU 2015-11, “Inventory: Simplifying the Measurement of Inventory.” The main provision of the guidance is that an entity should measure inventory at the lower of cost or net realizable value (“NRV”), where NRV is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company has adopted ASU 2016-09, “Compensation – Stock Compensation.” The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Adoption of this ASU did not have a material impact on the financial statements.

Inventory (Tables)

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Schedule of inventory

Major classifications of inventory are summarized as follows:



	June 30,		December 31,
	2017		2016
Feed	$	53,693	$	—
Fish in process	24,582		—
Total inventory	$	78,275	$	—

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

Major classifications of property, plant and equipment are summarized as follows:



	June 30,			December 31,
	2017			2016
Land	$	611,960		$	157,107
Building and improvements	8,558,012			1,436,814
Construction in process	2,235,659			277,352
Equipment	7,814,922			1,037,549
Office furniture and equipment	80,039			78,780
Vehicles	28,170			27,201
Total property and equipment	$	19,328,762		$	3,014,803
Less accumulated depreciation and amortization	(1,422,687		)	(1,291,096		)
Property, plant and equipment, net	$	17,906,075		$	1,723,707

Accounts payable and accrued liabilities (Tables)

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

Accounts payable and accrued liabilities include the following:



	June 30,		December 31,
	2017		2016
Accounts payable	$	366,927	$	161,768
Accrued payroll including vacation	244,077		242,436
Accrued professional fees	143,487		500,430
Accrued research and development costs	100,650		87,751
Accrued taxes	94,354		22,994
Accrued other	—		2,472
Accounts payable and accrued liabilities	$	949,495	$	1,017,851

Debt (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Schedule of debt

The current material terms and conditions of debt outstanding are as follows:



	Interest rate	Monthly repayment	Maturity date	June 30, 2017			December 31, 2016
ACOA AIF grant (C$2,871,919)	0%	Royalties	-	$	2,211,952		$	2,135,846
ACOA term loan (C$337,000)	0%	C$3,120	June 2026	257,154			—
Finance PEI term loan (C$717,093)	4%	C$4,333	July 2021	536,651			527,082
Total debt				$	3,005,757		$	2,662,928
less: current portion				(53,089		)	(17,913		)
Long-term debt				$	2,952,668		$	2,645,015

Schedule of maturities of debt

Estimated principal payments due on loan debt are as follows (1):



Year	Total
2017	$	23,757
2018	58,144
2019	100,630
2020	262,247
2021	1,994,536
Thereafter	566,443
Total	$	3,005,757

(1) Repayments of the AIF grants are based on revenue projections for AquAdvantage Salmon.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Stockholders' equity (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of restricted stock activity

A summary of the Company’s unvested shares of restricted stock as of June 30, 2017, is as follows:



	Shares		Weighted average grant date fair value
Unvested at December 31, 2016	4,169		$	7.72
Granted	1,751		14.20
Vested	(1,532	)	7.88
Unvested at June 30, 2017	4,388		$	10.25

Schedule of stock option activity

The Company’s option activity under the 2006 Plan and the 2016 Plan is summarized as follows:



	Number of options		Weighted average exercise price
Outstanding at December 31, 2016	185,591		$	7.89
Issued	52,500		14.20
Exercised	(8,334	)	3.30
Expired	(2,554	)	19.50
Outstanding at June 30, 2017	227,203		$	9.39
Exercisable at June 30, 2017	179,500		$	8.17

Summary of options outstanding and exercisable

The following table summarizes information about options outstanding and exercisable at June 30, 2017:



Weighted average exercise price of outstanding options	Number of options outstanding	Weighted average remaining estimated life (in years)	Number of options exercisable	Weighted average exercise price of outstanding and exercisable options
$3.30	79,337	2.0	79,337
$3.60	800	5.0	800
$5.70	10,336	7.7	10,006
$6.90	29,038	3.9	28,016
$7.50	15,837	5.8	15,837
$9.60	8,300	8.2	8,300
$9.90	800	1.0	800
$10.50	1,600	6.0	1,600
$10.80	2,400	7.0	2,400
$14.20	52,500	9.8	6,149
$23.40	26,255	6.6	26,255
	227,203		179,500	$8.17

Basis of presentation (Details)			3 Months Ended	6 Months Ended
Basis of presentation (Details)	Jun. 22, 2017 USD ($)	Jan. 05, 2017	Jun. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Property, Plant and Equipment [Line Items]
Purchase of land, buildings, and equipment				$ 16,193,926	$ 728,748
Reverse stock split		0.0333
Cash balance			$ 7,991,382	$ 7,991,382	$ 1,929,659	$ 3,324,609	$ 1,313,421
Bell Fish Company, LLC aquaculture facility \| Facility
Property, Plant and Equipment [Line Items]
Purchase of land, buildings, and equipment	$ 14,200,000		$ 14,200,000

Risks and uncertainties (Details)	Jun. 30, 2017 USD ($) shares
A/F Protein, Inc.
Concentration Risk [Line Items]
Long-term investment (in shares) \| shares	216,281
Ownership percentage (less than)	1.00%
Cost basis	$ 21,628
Concentration of credit risk \| Cash \| Canada
Concentration Risk [Line Items]
Deposits in Canadian bank accounts	$ 90,926

Inventory (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory	$ 78,275	$ 0
Feed
Inventory [Line Items]
Inventory	53,693	0
Fish in process
Inventory [Line Items]
Inventory	$ 24,582	$ 0

Property, plant and equipment (Details) - USD ($)		3 Months Ended	6 Months Ended
Property, plant and equipment (Details) - USD ($)	Jun. 22, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 19,328,762	$ 19,328,762		$ 3,014,803
Less accumulated depreciation and amortization		(1,422,687)	(1,422,687)		(1,291,096)
Property, plant and equipment, net		17,906,075	17,906,075		1,723,707
Depreciation and amortization expense			84,717	$ 58,054
Purchase of land, buildings, and equipment			16,193,926	$ 728,748
Capital Additions \| Rollo Bay farm site
Property, Plant and Equipment [Line Items]
Additional amount committed to renovations			2,400,000
Land
Property, Plant and Equipment [Line Items]
Total property and equipment		611,960	611,960		157,107
Building and improvements
Property, Plant and Equipment [Line Items]
Total property and equipment		8,558,012	8,558,012		1,436,814
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment		2,235,659	2,235,659		277,352
Construction in process \| Rollo Bay farm site
Property, Plant and Equipment [Line Items]
Total property and equipment		2,200,000	2,200,000
Equipment
Property, Plant and Equipment [Line Items]
Total property and equipment		7,814,922	7,814,922		1,037,549
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment		80,039	80,039		78,780
Vehicles
Property, Plant and Equipment [Line Items]
Total property and equipment		28,170	28,170		$ 27,201
Facility \| Bell Fish Company, LLC aquaculture facility
Property, Plant and Equipment [Line Items]
Purchase of land, buildings, and equipment	$ 14,200,000	$ 14,200,000
Future obligations	0
Liabilities assumed	$ 0
Facility \| Capital Additions \| Bell Fish Company, LLC aquaculture facility
Property, Plant and Equipment [Line Items]
Additional amount committed to renovations			$ 1,500,000

Accounts payable and accrued liabilities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 366,927	$ 161,768
Accrued payroll including vacation	244,077	242,436
Accrued professional fees	143,487	500,430
Accrued research and development costs	100,650	87,751
Accrued taxes	94,354	22,994
Accrued other	0	2,472
Accounts payable and accrued liabilities	$ 949,495	$ 1,017,851

Debt - Schedule of Debt (Details)	6 Months Ended
Debt - Schedule of Debt (Details)	Jun. 30, 2017 CAD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2017 CAD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 CAD ($)	Aug. 31, 2016 USD ($)	Feb. 29, 2016	Jan. 31, 2009 USD ($)
Debt Instrument [Line Items]
Total		$ 3,005,757		$ 2,662,928
less: current portion		(53,089)		(17,913)
Long-term debt		$ 2,952,668		2,645,015
Government grant \| ACOA AIF Grant
Debt Instrument [Line Items]
Interest rate		0.00%	0.00%
Total		$ 2,211,952	$ 2,871,919	2,135,846	$ 2,871,919			$ 2,211,952
Term loan \| ACOA Term Loan
Debt Instrument [Line Items]
Interest rate		0.00%	0.00%				0.00%
Monthly repayment	$ 3,120
Total		$ 257,154	$ 337,000	0
Term loan \| Finance PEI Term Loan
Debt Instrument [Line Items]
Interest rate		4.00%	4.00%
Monthly repayment	$ 4,333
Total		$ 536,651	$ 717,093	$ 527,082	$ 717,093	$ 552,305

Debt - Debt Maturities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Year
2017	$ 23,757
2018	58,144
2019	100,630
2020	262,247
2021	1,994,536
Thereafter	566,443
Total	$ 3,005,757	$ 2,662,928

Debt - Narrative (Details)	1 Months Ended		6 Months Ended
Debt - Narrative (Details)	Feb. 29, 2016 USD ($)	Jan. 31, 2009 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 CAD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 CAD ($)	Aug. 31, 2016 USD ($)
Debt Instrument [Line Items]
Total long-term debt claimed			$ 3,005,757			$ 2,662,928
Interest expense on debt			10,523	$ 107,639
Government grant \| ACOA AIF Grant
Debt Instrument [Line Items]
Debt instrument term (in years)		5 years
Total long-term debt claimed		$ 2,211,952	$ 2,211,952		$ 2,871,919	2,135,846	$ 2,871,919
Royalty (as a percent)		10.00%
Interest rate			0.00%		0.00%
Term loan \| ACOA Term Loan
Debt Instrument [Line Items]
Debt instrument term (in years)	9 years
Total long-term debt claimed			$ 257,154		$ 337,000	0
Maximum borrowing capacity	$ 259,557
Interest rate	0.00%		0.00%		0.00%
Term loan \| Finance PEI Term Loan
Debt Instrument [Line Items]
Total long-term debt claimed			$ 536,651		$ 717,093	$ 527,082	$ 717,093	$ 552,305
Interest rate			4.00%		4.00%

Stockholders' equity - Narrative (Details)	6 Months Ended
Stockholders' equity - Narrative (Details)	Jun. 30, 2017 USD ($) vote $ / shares shares	Jun. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($) shares
Equity [Abstract]
Total authorized shares (in shares) \| shares	240,000,000
Preferred stock, share authorized (in shares) \| shares	40,000,000
Common stock, share authorized (in shares) \| shares	200,000,000		200,000,000
Number of votes per share of common stock \| vote	1
Shares of common stock reserved for the exercise of options (in shares) \| shares	227,203
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of stock options granted (in dollars per share) \| $ / shares	$ 4.55
Intrinsic value of options exercised in period	$ 43,420
Intrinsic value of options outstanding	441,390		$ 602,773
Intrinsic value of options exercisable	439,494		$ 597,872
Unearned share-based compensation expense to be expensed in future periods	216,447
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance (in shares) \| shares		450,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unearned share-based compensation expense	$ 44,982
Period of recognition	3 years
Award vesting period	3 years
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 36,682	$ 106,402
Period of recognition	3 years
Expiration period	10 years
Employee Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Employee Stock Option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Chairman \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 12,070	$ 8,260

Stockholders' equity - Restricted stock activity (Details) - Restricted Stock	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Shares
Unvested, beginning balance (in shares) \| shares	4,169
Granted (in shares) \| shares	1,751
Vested (in shares) \| shares	(1,532)
Unvested, ending balance (in shares) \| shares	4,388
Weighted average grant date fair value
Unvested, beginning balance (in dollars per share) \| $ / shares	$ 7.72
Granted (in dollars per share) \| $ / shares	14.20
Vested (in dollars per share) \| $ / shares	7.88
Unvested, ending balance (in dollars per share) \| $ / shares	$ 10.25

Stockholders' equity - Stock option activity (Details)	6 Months Ended
Stockholders' equity - Stock option activity (Details)	Jun. 30, 2017 $ / shares shares
Number of options
Outstanding, beginning balance (in shares) \| shares	185,591
Issued (in shares) \| shares	52,500
Exercised (in shares) \| shares	(8,334)
Expired (in shares) \| shares	(2,554)
Outstanding, ending balance (in shares) \| shares	227,203
Exercisable (in shares) \| shares	179,500
Weighted average exercise price
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 7.89
Issued (in dollars per share) \| $ / shares	14.20
Exercised (in dollars per share) \| $ / shares	3.30
Expired (in dollars per share) \| $ / shares	19.50
Outstanding, ending balance (in dollars per share) \| $ / shares	9.39
Exercisable (in dollars per share) \| $ / shares	$ 8.17

Stockholders' equity - Summary of options outstanding and exercisable (Details)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 8.17
Number of options outstanding (in shares)	227,203
Number of options exercisable (in shares)	179,500
Weighted average exercise price of exercisable options (in dollars per share) \| $ / shares	$ 8.17
$3.30
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 3.30
Number of options outstanding (in shares)	79,337
Weighted average remaining estimated life (in years)	2 years
Number of options exercisable (in shares)	79,337
$3.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 3.60
Number of options outstanding (in shares)	800
Weighted average remaining estimated life (in years)	5 years
Number of options exercisable (in shares)	800
$5.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 5.70
Number of options outstanding (in shares)	10,336
Weighted average remaining estimated life (in years)	7 years 8 months 12 days
Number of options exercisable (in shares)	10,006
$6.90
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 6.90
Number of options outstanding (in shares)	29,038
Weighted average remaining estimated life (in years)	3 years 10 months 24 days
Number of options exercisable (in shares)	28,016
$7.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 7.50
Number of options outstanding (in shares)	15,837
Weighted average remaining estimated life (in years)	5 years 9 months 18 days
Number of options exercisable (in shares)	15,837
$9.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 9.60
Number of options outstanding (in shares)	8,300
Weighted average remaining estimated life (in years)	8 years 2 months 12 days
Number of options exercisable (in shares)	8,300
$9.90
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 9.90
Number of options outstanding (in shares)	800
Weighted average remaining estimated life (in years)	1 year
Number of options exercisable (in shares)	800
$10.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 10.50
Number of options outstanding (in shares)	1,600
Weighted average remaining estimated life (in years)	6 years
Number of options exercisable (in shares)	1,600
$10.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 10.80
Number of options outstanding (in shares)	2,400
Weighted average remaining estimated life (in years)	7 years
Number of options exercisable (in shares)	2,400
$14.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 14.20
Number of options outstanding (in shares)	52,500
Weighted average remaining estimated life (in years)	9 years 9 months 18 days
Number of options exercisable (in shares)	6,149
$23.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted average price of outstanding options (in dollars per share) \| $ / shares	$ 23.40
Number of options outstanding (in shares)	26,255
Weighted average remaining estimated life (in years)	6 years 7 months 6 days
Number of options exercisable (in shares)	26,255

Related Party Collaboration Agreement (Details) - Intrexon Corporation - ECC Agreement - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Accounts Payable and Accrued Liabilities
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities	$ 49,119		$ 73,780
Research and Development Expense
Related Party Transaction [Line Items]
Service costs incurred	$ 315,116	$ 489,083

Subsequent Events (Details) - Subsequent Event - Office space in Maynard, Massachusetts $ in Thousands	1 Months Ended
	Jul. 31, 2017 USD ($)
Subsequent Event [Line Items]
Lease term	5 years 7 months
Initial annual rent payments	$ 60
Annual rent payments during term of lease	$ 68